FLORANSA, 6 Temmuz 2023 - Dün akşam, Menarini Uluslararası Fair Play Ödülleri'nin XXVII. organizasyonunun büyük finali, Fiesole'deki Roma Tiyatrosunda binden fazla seyirci tarafından coşkuyla izlendi. Menarini Fair Play Vakfı tarafından düzenlenen, sporda fair play ve saygı kültürüne odaklanan etkinlik, ilk kez bu görkemli sahnede düzenlenen törenle sona erdi.

FLORENCE, Italy, 14th May 2023 -- Dönemin kültürünü hassasiyetle yorumlayan başarılı bir sanatçı ve olağanüstü eserlerin yaratıcısı olan Sandro Botticelli, bir güzellik dehasıydı.  Sanatçı, "Venüsler" sayesinde farkında olmadan günümüzü başarıyla yansıtan bir mükemmellik anlayışı oluşturmuştur. 

FLORENCE, Italy and NEW YORK, NY, August 19, 2022 -- The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of the Menarini Group, today announced that EMA has validated the Marketing Authorization Application (MAA) for elacestrant, a selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer. Validation of the application confirms the submission is complete and begins EMA’s centralized review procedure.

FLORENCE, Italy and NEW YORK, NY, August 11, 2022 -- The Menarini Group (“Menarini”), a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of Menarini Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for elacestrant, an investigational selective estrogen receptor degrader (SERD), for patients with ER+/HER2- advanced or metastatic breast cancer. The FDA has granted the application Priority Review and assigned a PDUFA date of February 17, 2023.

PHILADELPHIA, PA and FLORENCE, Italy— August 02, 2022—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, and The Menarini Group (“Menarini”) today announced a clinical trial collaboration and supply agreement for Menarini’s oral selective estrogen receptor degrader (SERD), elacestrant.